Fms-like tyrosine kinase 3 (FLT3) and Tubulin beta chain (FLT3/Tubulin)

The combination of Fms-like tyrosine kinase 3 (FLT3) and Tubulin beta chain (microtubules) represents a dual-target therapeutic strategy primarily focused on treating Acute Myeloid Leukemia (AML). FLT3 is a class III receptor tyrosine kinase that plays a pivotal role in the proliferation and survival of hematopoietic progenitor cells, with mutations like FLT3-ITD being significant drivers of leukemogenesis (Source: UniProt P36888). Tubulin beta chain is a structural protein that polymerizes into microtubules, essential for mitotic spindle formation and cell division (Source: UniProt P07437). Dual inhibitors, such as the anthelmintic drug mebendazole and experimental compounds like BPR1J-097, target both the kinase domain of FLT3 and the colchicine-binding site of tubulin (Source: PubMed 26138681, 22435996). This multi-targeted approach aims to overcome drug resistance and enhance clinical efficacy by simultaneously disrupting oncogenic signaling pathways and inducing mitotic arrest in cancer cells.

Other names

FLT3 and MicrotubulesCD135 and Beta-tubulinFetal liver kinase 2 and TubulinFLK-2 and Microtubules

Simultaneous inhibition of FLT3 receptor tyrosine kinase activity and disruption of microtubule polymerization, leading to cell cycle arrest and apoptosis.